Biotechnology and life sciences
The Munich Metropolitan Region (EMM) is a stand-out venue for Germany's biotechnology and pharmaceutical industries.
Broad range from research organizations to specialized startups
The Munich Metropolitan Region (EMM) is a stand-out venue for Germany's biotechnology and pharmaceutical industries. 21 % of biotechnology companies in Germany have their headquarters in the EMM, and 25 % of national clinical studies are carried out here.
This prominent position is made all the more remarkable by the intensity of global competition in this dynamic industry.
Munich - strong rise of employment in biotech
According to our new 2021 industry report , in 2020, the EMM accounted for 373 companies, employing some 33,400 people.
The number of employees has risen particularly sharply over the past eight years. Here biotech companies showed the strongest growth in employment - a plus of 91 percent. They now employ around 18,500 people.
Encouragingly, the number of startups has risen continuously since the last study and has even increased fivefold since 2015. According to Ernst & Young's German Biotechnology Report , 21 % of the new biotech startups founded last year in Germany are located in the Munich region. Overall, the country shows a clear north-south divide, with the Munich region among the leaders.
Nationwide and international players such as Amgen GmbH, Aenova, Bavarian Nordic GmbH, Bio-Rad Laboratories GmbH, Neovii Biotech GmbH, GE Healthcare Deutschland, GlaxoSmithKline (GSK), Hexal, Morphosys and Roche Diagnostics are based in the City or the greater Munich area.
Science and networks
The region is characterized by eight research institutions which provide the scientific foundation, including two elite universities, three world-renowned Max Planck Institutes, and the Helmholtz Center for Environmental Health.
Additionally, effective network management, in particular by the cluster organization BioM , both encourages and supports collaboration between business and science. Partnerships between companies, the proximity to cutting-edge research, and a vibrant network all help to make the EMM an appealing location for established companies and innovative start-ups alike.
Biotechnology and pharmaceuticals cluster
Recognized and effective network management has been provided by cluster organization BioM for over two decades now. BioM encourages dialog between the scientific and business communities, canvases for grants and subsidies, and until 2015 managed the leading-edge cluster M4, which focuses on the attractive, forward-looking fields of personalized medicine and targeted therapies. This effectively contributed to rising Munich's image as a reknowned location in the field.
In the biomedicine segment, the Grosshadern hospital, LMU's Gene Center and the Max Planck Institutes for Biochemistry and Neurobiology are already networking closely in Grosshadern-Martinsried in the southwest of Munich. In addition, the new BMC biomedical center was opened in 2015 on the LMU's high-tech campus in Grosshadern.
Research in Freising-Weihenstephan to the north of Munich is concentrated on agricultural, biotech and food science. Alongside the Weihenstephan-Triesdorf University of Applied Sciences, this location also hosts significant activities of the IZB Innovation and Start-up Center for Biotechnology.
Last updated: October 2021